Related Funds
Fund Name | Location |
BoostLAB | - |
China Environmental Fund | Beijing, Beijing, China |
EnCana | Alberta, Calgary, Canada |
Harrison Street Real Estate Capital | Chicago, Illinois, United States |
Horizons Labs | - |
Kaibang Ziben | Beijing, Beijing, China |
Nanjing Jiangbei New District Service Trade Innovation Development Fund | China, Jiangsu, Nanjing |
Orfin Ventures | Bloomfield Hills, Michigan, United States |
Ovctek China | Anhui, China, Hefei |
Quake Capital Partners | Austin, Texas, United States |
Royal Society Enterprise Fund | England, London, United Kingdom |
Saarbruecker 21 | Berlin, Berlin, Germany |
Schoffstall Ventures | Harrisburg, Pennsylvania, United States |
Stafford Capital Partners | Boston, Massachusetts, United States |
The R-Group, LLC | Oregon, Portland, United States |
Touchstone Ventures | Central, Central Region, Singapore |
Windcrest Partners | New York, New York, United States |
Wingtech Technology | China, Shanghai |
Woman Spark | Ar Riyad, Riyadh, Saudi Arabia |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Cantai Therapeutics | $700K | 20 Nov 2023 | - | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
Vittoria Biotherapeutics | $10M | 07 Jun 2022 | Philadelphia, Pennsylvania, United States | ||
Dianthus Therapeutics | $100M | 19 Apr 2022 | Waltham, Massachusetts, United States | ||
Navrogen | $3M | 09 Aug 2021 | Philadelphia, Pennsylvania, United States | ||
Interius BioTherapeutics | $76M | 18 May 2021 | Philadelphia, Pennsylvania, United States | ||
Zenas BioPharma | 23 Mar 2021 | - | |||
TamuroBio | 01 Jan 2021 | Mclean, Virginia, United States | |||
Aegle Therapeutics | $6M | 29 Sep 2020 | Miami, Florida, United States |
– Navrogen, Inc. from Cheyney, Pa. raises $3.0M in equity financing.
– The financing was led by Tellus BioVentures along with existing investors.
– The company intends to use the funds to advance its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Cantai Therapeutics | $700K | 20 Nov 2023 | - | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
Vittoria Biotherapeutics | $10M | 07 Jun 2022 | Philadelphia, Pennsylvania, United States | ||
Dianthus Therapeutics | $100M | 19 Apr 2022 | Waltham, Massachusetts, United States | ||
Navrogen | $3M | 09 Aug 2021 | Philadelphia, Pennsylvania, United States | ||
Interius BioTherapeutics | $76M | 18 May 2021 | Philadelphia, Pennsylvania, United States | ||
Zenas BioPharma | 23 Mar 2021 | - | |||
TamuroBio | 01 Jan 2021 | Mclean, Virginia, United States | |||
Aegle Therapeutics | $6M | 29 Sep 2020 | Miami, Florida, United States |